PR Newswire Clinical TrialsOriginal article
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
Phase 1approved[²²⁵Ac]Ac-FL-261Positive
AI Analysis
Summary
Full-Life Technologies announced FDA IND clearance and Australian regulatory approval for the Phase 1 clinical trial of [²²⁵Ac]Ac-FL-261, an actinium-based radiopharmaceutical candidate. The dual regulatory approvals enable the company to initiate clinical development in both the U.S. and Australia.
Clinical Trial Data
Phase
Phase 1
Outcome Details
U.S. FDA IND clearance and Australian regulatory clearance granted for Phase 1 clinical trial
Importance:7/10
Sentiment:
0.80
IND clearanceFDA approvalPhase 1radiopharmaceuticalactinium-basedinternational expansion
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 12:25 PM